Finnegan, Henderson, Farabow, Garrett & Dunner
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, one of the largest intellectual property law firms in the world, has joined the leasing momentum into Seaport's "Innovation District." Strategically located near the John Joseph Moakley United States Courthouse, Finnegan plans to continue accelerating in an environment conducive to achieving business growth and cultivating opportunity. (Full Article)
Ironwood Pharmaceuticals, a John Leonard client since early 2006, just got their first product FDA approved. It is expected to be available in the fourth quarter of 2012. Ironwood's success is very much apparent to us and we are honored to provide talent that has helped our client achieve these exciting milestones.
Associated Early Care and Education
Boston Business Journal recently highlighted Associated Early Care and Education's President and CEO, Wayne Ysaguirre, for his "innate affinity for early childhood education." Wayne has dedicated over ten years to the century old, Boston-based nonprofit that provides young children from birth to age five a stable support network and the resources for healthy growth and school readiness. (Full Article). We are excited to watch Associated Early Care and Education grow, particularly with their state-of-the-art learning center project, and will continue to suppor them while they make a difference in so many lives.
Our client, Ironwood Pharmaceuticals, is making great strides in the pharmaceutical industry. This Cambridge-based drug development company recently submitted a New Drug Application for its irritable bowel syndrome and chronic constipation drug candidate, linaclotide. Partnered with Forest Laboratories Inc., linaclotide yielded positive results in four Phase 3 trials across both indications. Ironwood continues to advance its pipeline, which includes product candidates and research efforts focused on gastrointestinal disease, pain and inflammation, respiratory and allergic disease, and cardiovascular disease. (Full Article)
We are excited to watch the progression of Ironwood Pharmaceuticals' success while continuing to support them in their company expansion.